Intrexon to achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, as new President and CEO and will change name to Precigen to reflect healthcare focus

Inextron Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the plate, announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO. The new Precigen will encompass Intrexon’s wholly-owned healthcare subsidiaries Precigen, ActoBio Therapeutics, Exemplar Genetics, and its majority ownership interest in Triple-Gene, as well as equity and royalty interests in therapeutics and therapeutic platforms from companies not controlled by Intrexon.

Read Full Press Release